Abstract A75: The IMPaCT trial: Individualised Molecular Pancreatic Cancer Therapy. A pilot, randomized, open label Phase II trial assessing first line treatment with gemcitabine or personalized treatment based on tumour molecular signature in patients with metastatic pancreatic cancer.

Mapping Intimacies ◽

10.1158/1535-7163.targ-13-a75 ◽

2013 ◽

Author(s):

Lorraine Chantrill ◽

Amber Johns ◽

Adnan Nagrial ◽

Venessa Chin ◽

Angela Chou ◽

...

Keyword(s):

Pancreatic Cancer ◽

Phase Ii Trial ◽

Molecular Signature ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

Pancreatic Cancer Therapy ◽

The Impact ◽

First Line Treatment

Download Full-text

Dose-adjusted EPOCH regimen as first-line treatment for non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis: a single-arm, open-label, phase II trial

Haematologica ◽

10.3324/haematol.2019.220301 ◽

2019 ◽

Vol 105 (1) ◽

pp. e29-e32 ◽

Cited By ~ 2

Author(s):

Jin-Hua Liang ◽

Li Wang ◽

Hua-Yuan Zhu ◽

Jun Qian ◽

Hui Liao ◽

...

Keyword(s):

Hodgkin Lymphoma ◽

Phase Ii ◽

Hemophagocytic Lymphohistiocytosis ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Non Hodgkin Lymphoma ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

Bevacizumab versus placebo in combination with paclitaxel and carboplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase II trial

ESMO Open ◽

10.1016/j.esmoop.2021.100313 ◽

2021 ◽

Vol 6 (6) ◽

pp. 100313

Author(s):

T. Zhou ◽

Y. Yang ◽

S. Ma ◽

L. Lin ◽

T. Zhou ◽

...

Keyword(s):

Nasopharyngeal Carcinoma ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Metastatic Nasopharyngeal Carcinoma ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

Multicenter, randomized, open-label Phase II study comparing S-1 alternate-day oral therapy with the standard daily regimen as a first-line treatment in patients with unresectable advanced pancreatic cancer

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-017-3250-8 ◽

2017 ◽

Vol 79 (4) ◽

pp. 813-823 ◽

Cited By ~ 7

Author(s):

Hiroki Yamaue ◽

Atsushi Shimizu ◽

Yasuhiro Hagiwara ◽

Masayuki Sho ◽

Hiroaki Yanagimoto ◽

...

Keyword(s):

Pancreatic Cancer ◽

Oral Therapy ◽

Phase Ii Study ◽

Advanced Pancreatic Cancer ◽

Daily Regimen ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the ‘burden of therapy’ method

European Journal of Cancer ◽

10.1016/j.ejca.2020.12.029 ◽

2021 ◽

Vol 146 ◽

pp. 95-106

Author(s):

M. Haas ◽

D.T. Waldschmidt ◽

M. Stahl ◽

A. Reinacher-Schick ◽

J. Freiberg-Richter ◽

...

Keyword(s):

Pancreatic Cancer ◽

Phase Ii ◽

Metastatic Pancreatic Cancer ◽

Integrated Analysis ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

BRIDGE: An open-label phase II trial evaluating the safety of bevacizumab (BV) plus paclitaxel/carboplatin (PC) as first-line treatment (tx) for patients (pts) with advanced, previously untreated, squamous non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.7583 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 7583-7583

Author(s):

L. Faoro ◽

J. D. Hainsworth ◽

D. A. Karlin ◽

J. E. Huang ◽

L. Fang ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii Trial ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

BRIDGE: An Open-Label Phase II Trial Evaluating the Safety of Bevacizumab + Carboplatin/Paclitaxel as First-Line Treatment for Patients with Advanced, Previously Untreated, Squamous Non-small Cell Lung Cancer

Journal of Thoracic Oncology ◽

10.1097/jto.0b013e3181f94ad4 ◽

2011 ◽

Vol 6 (1) ◽

pp. 109-114 ◽

Cited By ~ 41

Author(s):

John D. Hainsworth ◽

Liang Fang ◽

Jane E. Huang ◽

David Karlin ◽

Kenneth Russell ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii Trial ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

P1-17-01: Figitumumab Plus Exemestane Versus Exemestane as First-Line Treatment of Postmenopausal Hormone Receptor-Positive Advanced Breast Cancer: A Randomized, Open-Label Phase II Trial.

10.1158/0008-5472.sabcs11-p1-17-01 ◽

2011 ◽

Cited By ~ 4

Author(s):

PD Ryan ◽

P Neven ◽

KL Blackwell ◽

LY Dirix ◽

CH Barrios ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Hormone Receptor ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Hormone Receptor Positive ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

P3-14-15: Non-Randomized, Open Label Phase II Trial Evaluating the Safety and Efficacy of Taxotere (T) Followed by Myocet (M) + Cyclophosphamide (C) as First-Line Treatment for HER2−Negative Breast Cancer (BC).

10.1158/0008-5472.sabcs11-p3-14-15 ◽

2011 ◽

Cited By ~ 1

Author(s):

J García-Mata ◽

L Calvo ◽

R López ◽

M Ramos ◽

J Castellanos ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Safety And Efficacy ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

Dose-Adjusted EPOCH Regimen as First-Line Treatment for Non-Hodgkin's Lymphoma with Hemophagocytic Lymphohistiocytosis: A Single-Arm, Open-Label, Phase 2 Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3304299 ◽

2018 ◽

Author(s):

Jin-Hua Liang ◽

Li Wang ◽

Hua-Yuan Zhu ◽

Jun Qian ◽

Hui Liao ◽

...

Keyword(s):

Hemophagocytic Lymphohistiocytosis ◽

Hodgkin's Lymphoma ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Open Label ◽

Phase 2 Trial ◽

Non Hodgkin's Lymphoma ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

69 Afatinib versus gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC) harbouring activating EGFR mutations: results of the global, randomised, open-label, phase IIb trial LUX-Lung 7

Lung Cancer ◽

10.1016/s0169-5002(16)30086-1 ◽

2016 ◽

Vol 91 ◽

pp. S25

Author(s):

K.J. O'Byrne ◽

K. Park ◽

E. Tan ◽

L. Zhang ◽

V. Hirsh ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Egfr Mutations ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

First Line Treatment

Download Full-text